The XXII chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the XXII chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The XXII stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View XXII Detailed Price Forecast - CNN Money||View XXII Detailed Summary - Google Finance|
|View XXII Detailed Summary - Yahoo! Finance||View XXII Stock Research & Analysis - Zacks.com|
|View XXII Trends & Analysis - Trade-Ideas||View XXII Major Holders - Barrons|
|View XXII Call Transcripts - NASDAQ||View XXII Breaking News & Analysis - Seeking Alpha|
|View XXII Annual Report - CompanySpotlight.com||View XXII OTC Short Report - OTCShortReport.com|
|View XXII Fundamentals - TradeKing||View XXII SEC Filings - Bar Chart|
|View Historical Prices for XXII - The WSJ||View Performance/Total Return for XXII - Morningstar|
|View the Analyst Estimates for XXII - MarketWatch||View the Earnings History for XXII - CNBC|
|View the XXII Earnings - StockMarketWatch||View XXII Buy or Sell Recommendations - MacroAxis|
|View the XXII Bullish Patterns - American Bulls||View XXII Short Pain Metrics - ShortPainBot.com|
|View XXII Stock Mentions - StockTwits||View XXII Stock Mentions - PennyStockTweets|
|View XXII Stock Mentions - Twitter||View XXII Investment Forum News - Investor Hub|
|View XXII Stock Mentions - Yahoo! Message Board||View XXII Stock Mentions - Seeking Alpha|
|View Insider Transactions for XXII - SECform4.com||View Insider Transactions for XXII - Insider Cow|
|View XXII Major Holdings Summary - CNBC||View Insider Disclosure for XXII - OTC Markets|
|View Insider Transactions for XXII - Yahoo! Finance||View Institutional Holdings for XXII - NASDAQ|
|View XXII Stock Insight & Charts - FinViz.com||View XXII Investment Charts - StockCharts.com|
|View XXII Stock Overview & Charts - BarChart||View XXII User Generated Charts - Trading View|
If You Had Bought 22nd Century Group (NYSEMKT:XXII) Stock A Year Ago, You'd Be Sitting On A 50% Loss, Today
Posted on Wednesday January 22, 2020
It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...
22nd Century Group Appoints New Director and New Chairman
Posted on Monday January 13, 2020
Williamsville, NY, Jan. 13, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced the appointment of Roger O’Brien as a new member of 22nd Century Group’s Board of Directors (the “Board”) and the appointment of Nora Sullivan, an existing director of the Board, as the new Chairman of the Board.
22nd Century Group to Present its Modified Risk Tobacco Product Application to FDA’s Tobacco Products Scientific Advisory Committee
Posted on Monday December 23, 2019
Williamsville, NY, Dec. 23, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced today that the U.S. Food and Drug Administration's (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) will conduct a public hearing on Friday, February 14, 2020, regarding 22nd Century Group’s Modified Risk Tobacco Product (MRTP) application for its VLNC cigarettes under the proposed brand name of VLN® cigarettes. “We welcome the opportunity to publicly present our MRTP application and detail the science and evidence supporting the reduced exposure claims for VLN® cigarettes,” said Michael Zercher, President and Chief Operating Officer of 22nd Century Group.
FDA Authorizes Marketing of 22nd Century Group’s Proprietary Moonlight® and Moonlight® Menthol Cigarettes
Posted on Tuesday December 17, 2019
Williamsville, NY, Dec. 17, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco, and hemp/cannabis plant research, announced today that the U.S. Food and Drug Administration (FDA) has found that the marketing of 22nd Century Group’s proprietary Moonlight® and Moonlight® Menthol brand cigarettes are “appropriate for the protection of the public health,” and the FDA has issued marketing orders to permit the sale of these products in the U.S. This FDA authorization follows the FDA’s review of the Premarket Tobacco Product Applications (PMTA) previously submitted by 22nd Century Group. “FDA authorization of 22nd Century’s proprietary Moonlight® and Moonlight® Menthol brand cigarettes is a major milestone in our efforts to drive meaningful change in the tobacco industry,” said Michael Zercher, President and Chief Operating Officer of 22nd Century Group.